Thus, the localization of IL-1β in GM lesions may explain some clinical deficits which cannot be attributed solely to the presence of IL-1β in WM lesions, and is therefore of potential interest for the pathogenesis and treatment of MS patients with GM lesion-related deficits. This evidence concerns the gene IL1B and myeloid sarcoma.